Clinuvel Pharmaceuticals (ASX:CUV) said it expects the ongoing US Federal Government shutdown to impact the deadline for the upgrade of its American Depositary Receipt Level program from level one to level two, according to a Monday filing with the Australian bourse.
The US administration expects a longer turnaround time for the review and approval of the registration statements filed with the US Securities and Exchange Commission, the filing said.
The review and approval are expected to be completed only after the shutdown is resolved, the filing added.
Shares of the company fell nearly 1% in recent Monday trade.